GenOway: Solid 2024 Results and Strategic Ambitions with ROUTE 50+

Biotechnology company genOway has published its 2024 annual results, posting EBITDA of €4.4 million with a margin of 20.1%, and net income of €1.8 million, up 17%. Revenue totaled €22.1 million, marking organic growth of 10%. This performance illustrates the resilience of its business model despite a challenging market.

genOway's future strategy, via the ROUTE 50+ plan, aims for growth through innovation, particularly in immuno-oncology. The company plans to reorganize its sales teams by 2025, while building on the success of its joint venture in Shanghai.

With equity of €17.9 million and positive net cash flow, genOway is committed to maintaining an EBITDA margin above 15% in 2025 despite economic challenges.